安裝中文字典英文字典辭典工具!
安裝中文字典英文字典辭典工具!
|
- ENJAYMO® (sutimlimab-jome) | Cold Agglutinin Disease Treatment
ENJAYMO is the first and only FDA-approved treatment for people with cold agglutinin disease (CAD) to help decrease the need for red blood cell transfusion For U S Residents Only ENJAYMO Patient Solutions ( 1-833-223-2428 )
- Sutimlimab - Wikipedia
Sutimlimab, sold under the brand name Enjaymo, is a monoclonal antibody that is used to treat adults with cold agglutinin disease (CAD) [ 1 ] [ 3 ] [ 4 ] It is given by intravenous infusion [ 1 ] Sutimlimab prevents complement-enhanced activation of autoimmune human B cells in vitro
- Enjaymo: Uses, Dosage, Side Effects Warnings - Drugs. com
Enjaymo is a prescription medicine that affects your immune system Enjaymo can lower the ability of your immune system to fight infections People who take Enjaymo may have an increased risk of getting infections caused by certain kinds of bacteria such as Neisseria meningitides, Streptococcus pneumoniae, and Haemophilus influenzae
- FULL PRESCRIBING INFORMATION 1 INDICATIONS AND USAGE
ENJAYMO (sutimlimab-jome) is indicated for the treatment of hemolysis in adults with cold agglutinin disease (CAD) 2 DOSAGE AND ADMINISTRATION 2 1 Recommended Vaccinations Vaccinate patients against encapsulated bacteria at least 2 weeks prior to initiation of ENJAYMO therapy according to the most current Advisory Committee on Immunization
- ENJAYMO® (sutimlimab-jome) | Healthcare Professional Website
ENJAYMO, a proximal classical complement C1s inhibitor, increases susceptibility to serious infections, including those caused by encapsulated bacteria e g Neisseria meningitidis (any serogroup, including non-groupable strains), Streptococcus pneumoniae, and Haemophilus influenzae type B
- Enjaymo | European Medicines Agency (EMA)
Enjaymo is a medicine for treating haemolytic anaemia (excess breakdown of red blood cells) in adults with cold agglutinin disease (CAD) CAD is a rare blood disorder where the immune system (the body’s natural defence) recognises red blood cells as foreign and attacks them
- HIGHLIGHTS OF PRESCRIBING INFORMATION . . . - Sanofi
ENJAYMO intravenously weekly for the first two weeks, with administration every two weeks thereafter Administer ENJAYMO at the recommended dosage regimen time points, or within two days of these time points If a dose is missed, administer as soon as possible; thereafter, resume dosing every two weeks
- Enjaymo (sutimlimab): Uses, Side Effects, Dosage Reviews
This is because Enjaymo (sutimlimab) can raise your risk for serious infections You must receive these vaccines at least 2 weeks before starting Enjaymo (sutimlimab) treatment If your provider decides you need to start Enjaymo (sutimlimab) right away, it's important to get these vaccines as soon as possible to prevent infections
|
|
|